Lisa A. Hayes
Nessuna posizione attualmente
Profilo
Lisa A.
Hayes worked as Senior Director of Investor Relations at Celgene Corp.
and as Head of Investor Relations & Corporate Communications at ProQR Therapeutics NV and Tmunity Therapeutics, Inc. She also worked as VP of Investor Relations & Corporate Communications at Cyteir Therapeutics, Inc. from 2021 to 2023.
Ms. Hayes holds a graduate degree from New York University, a Master's in Business Administration from St. Joseph's University, and an undergraduate degree from Seton Hall University.
Precedenti posizioni note di Lisa A. Hayes
Società | Posizione | Fine |
---|---|---|
CYTEIR THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 01/02/2023 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Contatto Relazioni con gli Investitori | - |
PROQR THERAPEUTICS N.V. | Contatto Relazioni con gli Investitori | - |
CELGENE | Public Communications Contact | - |
Formazione di Lisa A. Hayes
St. Joseph's University | Masters Business Admin |
New York University | Graduate Degree |
Seton Hall University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
PROQR THERAPEUTICS N.V. | Health Technology |
CYTEIR THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
- Borsa valori
- Insiders
- Lisa A. Hayes